Mark Erlander
Net Worth

Last updated:

What is Mark Erlander net worth?

The estimated net worth of Dr. Mark Erlander is at least $6,125,676 as of 25 Nov 2022. He owns shares worth $56,796 as insider and has received compensation worth at least $6,068,880 in Cardiff Oncology, Inc..

What is the salary of Mark Erlander?

Dr. Mark Erlander salary is $674,320 per year as Chief Executive Officer & Director in Cardiff Oncology, Inc..

How old is Mark Erlander?

Dr. Mark Erlander is 65 years old, born in 1960.

What stocks does Mark Erlander currently own?

As insider, Dr. Mark Erlander owns shares in one company:

Company Title Shares Price per share Total value
Cardiff Oncology, Inc. (CRDF) Chief Executive Officer & Director 24,481 $2.32 $56,796

What does Cardiff Oncology, Inc. do?

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

CRDF logo
CRDF
Cardiff Oncology, Inc.
$2.32

Mark Erlander insider trading

Cardiff Oncology, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 10,000 $1.43 $14,300
Purchase
Common Stock 965 $10.34 $9,980
Option
Common Stock 260 N/A N/A
Option
Restricted Stock Units 260 N/A N/A
Purchase
Common Stock 6,993 $1.43 $10,000
Option
Common Stock 261 N/A N/A
Option
Restricted Stock Units 261 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 1,563 N/A N/A
Option
Restricted Stock Units 1,563 N/A N/A
Option
Common Stock 7,500 N/A N/A
Option
Restricted Stock Units 7,500 N/A N/A
Option
Common Stock 7,500 N/A N/A
Option
Restricted Stock Units 7,500 N/A N/A
Option
Common Stock 90,000 N/A N/A
Option
Restricted Stock Units 90,000 N/A N/A
Option
Restricted Stock Units 18,750 N/A N/A
Option
Common Stock 37,500 N/A N/A
Option
Common Stock 30,001 N/A N/A
Option
Restricted Stock Units 30,001 N/A N/A
Option
Common Stock 50,000 N/A N/A
Option
Restricted Stock Units 50,000 N/A N/A
Purchase
Common Stock 5,000 $2.08 $10,375

Cardiff Oncology key executives

Cardiff Oncology, Inc. executives and other stock owners filed with the SEC: